ArticleAnnals of translational medicine2019

Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.

Zhonghan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.